Therapeutic advances: Paroxetine for the treatment of social anxiety disorder

被引:0
|
作者
Lydiard, RB
Bobes, J
机构
[1] Med Univ S Carolina, Psychopharmacol Unit, Dept Psychiat, Mood & Anxiety Disorders Program, Charleston, SC 29425 USA
[2] Univ Oviedo, Fac Med, Oviedo, Spain
关键词
social anxiety disorder; social phobia; clinical trial; randomized; placebo-controlled;
D O I
10.1002/(SICI)1520-6394(2000)11:3<99::AID-DA3>3.0.CO;2-Z
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Data from early studies of selective serotonin reuptake inhibitors have shown that these agents are effective in the treatment of social anxiety disorder (social phobia). This review highlights the outcomes of three large clinical trials of paroxetine in patients with social anxiety disorder. In two of the studies, patients received a flexible dose of paroxetine (20-50 mg/day) or placebo; the third trial was a fixed-dose study, in which patients received paroxetine 20, 40, or 60 mg/day, or placebo. A total of 861 subjects were randomized to treatment for 12 weeks, in centers across the U.S.A., Canada, Europe, and South Africa. The primary outcome measures were the Clinical Global Impressions (CGI) Global Improvement item and Liebowitz Social Anxiety Scale (LSAS) Total Score. In each of the studies, 45-66% of patients receiving paroxetine were rated as responders (very much or much improved on the CGI scale). Paroxetine treatment improved symptoms of social anxiety, as measured by the LSAS, compared with placebo. Differences between paroxetine and placebo groups were statistically significant and wee clinically relevant within each study. In general, paroxetine was well tolerated. Paroxetine is effective for the treatment of social anxiety disorder. Based on the findings from these studies, a starting dose of 20 mg/day is recommended. The range of efficacy appears to be 20-50 mg/day for most patients. (C) Wiley-Liss, Inc.
引用
收藏
页码:99 / 104
页数:6
相关论文
共 50 条
  • [1] Paroxetine in social phobia/social anxiety disorder
    Franklin R. Schneier
    [J]. Current Psychiatry Reports, 2000, 2 (4) : 326 - 326
  • [2] Paroxetine in the treatment of generalised anxiety disorder
    Snyderman, SH
    Rynn, MA
    Bellew, K
    Rickels, K
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (08) : 1799 - 1806
  • [3] Escitalopram and paroxetine in fixed doses for the treatment of social anxiety disorder (SAD)
    Montgomery, SA
    Lader, M
    Nil, R
    [J]. NORDIC JOURNAL OF PSYCHIATRY, 2003, 57 (02) : 103 - 103
  • [4] Fixed doses of escitalopram and paroxetine for the treatment of social anxiety disorder (SAD)
    Lader, M
    Stender, K
    Bürger, V
    Nil, R
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S364 - S364
  • [5] Controlled-release paroxetine in the treatment of patients with social anxiety disorder
    Lepola, U
    Bergtholdt, B
    St Lambert, J
    Davy, KL
    Ruggiero, L
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 (02) : 222 - 229
  • [6] An evaluation of paroxetine in generalised social anxiety disorder
    Van Ameringen, M
    Mancini, C
    Patterson, B
    Bennett, M
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (05) : 819 - 830
  • [7] Remission of pediatric social anxiety disorder with paroxetine
    Wagner, KD
    Wetherhold, E
    Gee, M
    Carpenter, DJ
    Machin, A
    Davy, K
    Perera, P
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2003, 13 (04) : 421 - 422
  • [8] Clinical experience with paroxetine in social anxiety disorder
    Baldwin, DS
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2000, 15 : S19 - S24
  • [9] Paroxetine in social anxiety disorder: A remission analysis
    Stein, DJ
    Hunter, B
    Rolfe, T
    Oakes, R
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S347 - S348
  • [10] Paroxetine treatment of generalized social phobia (social anxiety disorder) - A randomized controlled trial
    Stein, MB
    Liebowitz, MR
    Lydiard, RB
    Pitts, CD
    Bushnell, W
    Gergel, I
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (08): : 708 - 713